All updates
All updates
today 46临床试验登记评分2727 STAT News评分2727 STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug
监管与产业动态评分2222 Signal or noise? > Prula-cel Shows Early Promise in Lupus - The Medicine Maker >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #biotech #pharmaceutical
中文产业新闻Chinese source评分6262 胎盘间充质干细胞补片首次用于胎儿脊髓脊膜膨出宫内修复，6例结果在《柳叶刀》发表
中文产业新闻Chinese source评分6666 Cerevance帕金森FIC口服药solengepras 3期ARISE试验达主要终点
中文产业新闻Chinese source评分6161 艾力斯伏美替尼FURVENT全球三期未达主要终点
中文产业新闻精选Chinese source评分6868 恒瑞医药口服GLP-1受体激动剂safiglipron三期OUTSTAND-1试验显示降糖与体重获益
顶刊论文（社媒热度）精选评分7575 Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.
STAT News评分3939 STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
社区讨论（Reddit）评分4747 Gene Therapy Restores Partial Sight in Clinical Trial
中文产业新闻精选Chinese source评分6868 Kodiak Sciences 两款眼科药物 III 期 DAYBREAK 研究达到主要终点
中文产业新闻Chinese source评分5858 艾力斯伏美替尼海外FURVENT三期未达PFS主要终点，文章归因于同适应症竞品更强
中文产业新闻Chinese source评分6464 礼来在2026 EADV公布lebrikizumab治疗特应性手足皮炎ADtouch 3b期研究结果
中文产业新闻Chinese source评分6666 联邦制药UBT251注射液中国II期研究在EASD 2026公布降糖减重数据
中文产业新闻Chinese source评分6161 众生药业RAY1225三期数据公布：受试者一年减重近22%，两周一针给药
监管与产业动态精选评分7575 Cervical cancer trial finds similar early recovery results after robot-assisted versus open surgery
监管与产业动态评分6969 Argenx walks away from Vyvgart Sjögren's disease trial after futility flag - Fierce Pharma
中文产业新闻精选Chinese source评分7070 Argenx终止艾加莫德皮下制剂干燥综合征III期UNITY研究
中文产业新闻精选Chinese source评分7979 两款B7-H3 ADC三期同步读出OS获益，复发小细胞肺癌二线标准被重写
中文产业新闻Chinese source评分7070 信达生物信必敏®三期临床在非活动性甲状腺眼病中达主要终点
中文产业新闻Chinese source评分5858 艾力斯伏美替尼FURVENT试验未达到主要研究终点
中文产业新闻Chinese source评分3535 复宏汉霖：PD-L1/VEGF双抗启动一线NSCLC 2/3期临床
中文产业新闻Chinese source评分6565 Argenx跌12%：艾加莫德干燥综合征三期临床失败
中文产业新闻Chinese source评分6161 2026 IGCS会议公布ALTER-GO-010研究：安罗替尼一线维持治疗晚期卵巢癌中位PFS达27.43个月
中文产业新闻Chinese source评分6262 Kodiak ZenKuda 湿性 AMD 三期 DAYBREAK 顶线阳性，拟四季度申报 BLA
顶刊论文（社媒热度）精选评分7474 Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.
The Lancet精选评分6565 [Articles] Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial
中文产业新闻Chinese source评分2222 安泰康赛启动JMBI-001针对MYC阳性晚期实体瘤及复发/难治性非霍奇金淋巴瘤的Ⅰ/Ⅱ期临床试验
中文产业新闻Chinese source评分3535 复宏汉霖在中国启动HLX37联合化疗一线治疗晚期非小细胞肺癌的Ⅱ/Ⅲ期临床试验
中文产业新闻Chinese source评分3535 安进启动maridebart cafraglutide针对2型糖尿病的Ⅲ期临床试验，头对头司美格鲁肽
中文产业新闻Chinese source评分5858 艾力斯伏美替尼FURVENT全球三期未达主要终点
临床试验登记评分2727 Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
临床试验登记评分2929 Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer
临床试验登记评分2323 Clinical Study of Three-dimensional Lattice Radiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Advanced Solid Tumors
临床试验登记评分2727 De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer
临床试验登记评分3434 Neoadjuvant Chemoradiotherapy Combined With QL1706 for MSS-Type Low-Rectal Cancer
临床试验登记评分2929 Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer
临床试验登记评分3535 Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
临床试验登记评分3535 A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
中文产业新闻Chinese source评分6060 艾加莫德干燥综合征III期UNITY研究因无效性提前终止